Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NUVB Stock Forecast 2025-2026
$8.55
Current Price
$2.93B
Market Cap
Buy 9
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NUVB Price Targets
+40.4%
To High Target of $12.00
+17.0%
To Median Target of $10.00
-6.4%
To Low Target of $8.00
NUVB Price Momentum
+6.5%
1 Week Change
+80.8%
1 Month Change
+200.0%
1 Year Change
+221.4%
Year-to-Date Change
-1.7%
From 52W High of $8.70
+455.2%
From 52W Low of $1.54
📊 TOP ANALYST CALLS
Did NUVB Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Nuvation Bio is one of their latest high-conviction picks.
Latest NUVB Stock Price Targets & Analyst Predictions
Based on our analysis of 13 Wall Street analysts, NUVB has a bullish consensus with a median price target of $10.00 (ranging from $8.00 to $12.00). The overall analyst rating is Strong Buy (9.6/10). Currently trading at $8.55, the median forecast implies a 17.0% upside. This outlook is supported by 9 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Mayank Mamtani at B. Riley Securities, projecting a 40.4% upside. Conversely, the most conservative target is provided by Leonid Timashev at RBC Capital, suggesting a 6.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NUVB Analyst Ratings
9
Buy
0
Hold
0
Sell
NUVB Price Target Range
Low
$8.00
Average
$10.00
High
$12.00
Current: $8.55
Latest NUVB Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NUVB.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 1, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Nov 24, 2025 | Truist Securities | Gregory Renza | Buy | Initiates | $11.00 |
| Nov 20, 2025 | Citizens | Silvan Tuerkcan | Market Outperform | Maintains | $10.00 |
| Nov 19, 2025 | B. Riley Securities | Mayank Mamtani | Buy | Initiates | $12.00 |
| Nov 4, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $8.00 |
| Nov 4, 2025 | Citizens | Silvan Tuerkcan | Market Outperform | Maintains | $8.00 |
| Oct 13, 2025 | Wedbush | David Nierengarten | Outperform | Reiterates | $6.00 |
| Sep 30, 2025 | Jefferies | Farzin Haque | Buy | Initiates | $10.00 |
| Sep 19, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $10.00 |
| Sep 8, 2025 | Wedbush | David Nierengarten | Outperform | Reiterates | $6.00 |
| Aug 8, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $7.00 |
| Jun 25, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $6.00 |
| Jun 17, 2025 | RBC Capital | Leonid Timashev | Outperform | Maintains | $6.00 |
| Jun 11, 2025 | Wedbush | David Nierengarten | Outperform | Maintains | $5.00 |
| Jun 2, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Reiterates | $6.00 |
| May 16, 2025 | Wedbush | David Nierengarten | Outperform | Reiterates | $5.00 |
| Apr 23, 2025 | JMP Securities | Silvan Tuerkcan | Market Outperform | Initiates | $6.00 |
| Mar 12, 2025 | Jones Trading | Soumit Roy | Buy | Initiates | $10.00 |
| Mar 10, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $10.00 |
| Jan 23, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $11.00 |
Nuvation Bio Inc. (NUVB) Competitors
The following stocks are similar to Nuvation Bio based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nuvation Bio Inc. (NUVB) Financial Data
Nuvation Bio Inc. has a market capitalization of $2.93B with a P/E ratio of -4.1x. The company generates $26.75M in trailing twelve-month revenue with a 10.1% profit margin.
Revenue growth is +1,704.7% quarter-over-quarter, while maintaining an operating margin of -430.1% and return on equity of -52.5%.
Valuation Metrics
Market Cap
$2.93B
Enterprise Value
$2.38B
P/E Ratio
-4.1x
PEG Ratio
-0.6x
Price/Sales
104.9x
Growth & Margins
Revenue Growth (YoY)
+1,704.7%
Gross Margin
+74.5%
Operating Margin
-430.1%
Net Margin
+10.1%
EPS Growth
+1,704.7%
Financial Health
Cash/Price Ratio
+18.7%
Current Ratio
8.5x
Debt/Equity
17.7x
ROE
-52.5%
ROA
-24.8%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Nuvation Bio Inc. (NUVB) Business Model
About Nuvation Bio Inc.
What They Do
Develops innovative therapies for oncology patients.
Business Model
Nuvation Bio Inc. generates revenue through the research and development of novel drug candidates targeting various forms of cancer. The company collaborates with leading experts in oncological research and aims to bring promising treatments to clinical trials, focusing on areas with high unmet medical needs.
Additional Information
With a strategic emphasis on next-generation therapies, including small molecules and targeted drugs, Nuvation Bio Inc. is positioned in a competitive biotechnology landscape. Its advancements could significantly impact the healthcare sector, especially in transforming cancer treatment paradigms, making it an important consideration for investors interested in therapeutic innovation.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
291
CEO
Dr. David T. Hung M.D.
Country
United States
IPO Year
1999
Website
www.nuvationbio.comNuvation Bio Inc. (NUVB) Latest News & Analysis
Latest News
Nuvation Bio Inc. (NUVB) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
3 days ago
Quick Summary
Nuvation Bio Inc. (NUVB) presented at the Citi Annual Global Healthcare Conference 2025, discussing its developments and strategies in the healthcare sector.
Why It Matters
Nuvation Bio's presentation at a major healthcare conference can signal potential growth opportunities, partnerships, or breakthroughs, influencing investor sentiment and stock performance.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Nuvation Bio Inc. (NYSE: NUVB) reported positive Phase 2 study results for safusidenib, a targeted inhibitor for IDH1-mutant gliomas, published in Neuro-Oncology on November 8.
Why It Matters
Positive Phase 2 results for safusidenib may enhance Nuvation Bio's market position and attract investor interest, signaling potential revenue growth in oncology.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Nuvation Bio (NUVB) is downgraded from Buy to Hold. Ibtrozi's launch shows strong early uptake, with a revenue estimate of $300–$600 million, but current valuation limits upside potential.
Why It Matters
Nuvation Bio's downgrade signals a shift in valuation, reflecting strong fundamentals and revenue potential. This may indicate reduced upside for investors, affecting future buying decisions.
Source: Seeking Alpha
Market Sentiment:
Positive
Quick Summary
Nuvation Bio Inc. (NYSE: NUVB) executives will participate in fireside chats at the Evercore Healthcare Conference on December 2, 2025, at 9:35 a.m. ET in Miami, FL.
Why It Matters
Nuvation Bio's leadership participation in key investor conferences signals potential insights into their oncology developments, impacting investor sentiment and stock performance.
Source: Business Wire
Market Sentiment:
Neutral
Nuvation Bio Inc. (NUVB) Presents at Jefferies London Healthcare Conference 2025 Transcript
15 days ago
Quick Summary
Nuvation Bio Inc. (NUVB) will present at the Jefferies London Healthcare Conference on November 19, 2025, at 10:00 AM EST, featuring CEO David Hung and CFO Philippe Sauvage.
Why It Matters
Nuvation Bio's participation in a major healthcare conference signals potential visibility and interest from investors, which can impact stock performance and investor sentiment.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Nuvation Bio's Ibtrozi, FDA-approved for ROS1-positive lung cancer, gained 204 new patients last quarter, indicating strong market potential and supporting its revenue growth.
Why It Matters
Nuvation Bio's strong early sales of Ibtrozi indicate a promising revenue outlook, validating its market potential and supporting its current valuation, while global rights enhance growth prospects.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About NUVB Stock
What is Nuvation Bio Inc.'s (NUVB) stock forecast for 2026?
Based on our analysis of 13 Wall Street analysts, Nuvation Bio Inc. (NUVB) has a median price target of $10.00. The highest price target is $12.00 and the lowest is $8.00.
Is NUVB stock a good investment in 2026?
According to current analyst ratings, NUVB has 9 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.55. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NUVB stock?
Wall Street analysts predict NUVB stock could reach $10.00 in the next 12 months. This represents a 17.0% increase from the current price of $8.55. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nuvation Bio Inc.'s business model?
Nuvation Bio Inc. generates revenue through the research and development of novel drug candidates targeting various forms of cancer. The company collaborates with leading experts in oncological research and aims to bring promising treatments to clinical trials, focusing on areas with high unmet medical needs.
What is the highest forecasted price for NUVB Nuvation Bio Inc.?
The highest price target for NUVB is $12.00 from Mayank Mamtani at B. Riley Securities, which represents a 40.4% increase from the current price of $8.55.
What is the lowest forecasted price for NUVB Nuvation Bio Inc.?
The lowest price target for NUVB is $8.00 from Leonid Timashev at RBC Capital, which represents a -6.4% decrease from the current price of $8.55.
What is the overall NUVB consensus from analysts for Nuvation Bio Inc.?
The overall analyst consensus for NUVB is bullish. Out of 13 Wall Street analysts, 9 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $10.00.
How accurate are NUVB stock price projections?
Stock price projections, including those for Nuvation Bio Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: December 7, 2025 2:09 AM UTC